CD274 and non-small cell lung carcinoma: In a randomized, double-blind, phase 2 trial, 135 treatment-nave patients with unresectable and metastatic NSCLC, positive for PD-L1 expression, were treated with tiragolumab (or placebo) in combination with atezolizumab (anti-PD-L1) (NCT03563716) (Rodriguez-Abreu et al., 2020).